Key result
Anticoagulation therapy reversal and optimal resumption timing after intracranial hemorrhage currently lack high-quality evidence from large randomized controlled trials.
Why the study?
Quality evidence and large randomized controlled trials regarding the reversal of anticoagulant effects and optimal timing of anticoagulant resumption after intracranial hemorrhage in patients with AF are lacking.
What is the optimal strategy for reversing anticoagulant effects and resuming therapy in patients with atrial fibrillation after intracranial hemorrhage?
What is the optimal strategy for reversing anticoagulant effects and resuming therapy in patients with atrial fibrillation after intracranial hemorrhage?
Current clinical guidelines for managing anticoagulation in AF patients post-ICH rely on retrospective data and expert opinion, highlighting the need for upcoming RCT results.
Decisions on anticoagulation reversal and resumption after ICH should remain individualized; leaves open the need for dedicated large RCTs.
Intracerebral hemorrhage (ICH) is severe and fatal complication of anticoagulant therapy with an incidence 0.3-0.7% per year. For patients with atrial fibrillation (AF) anticoagulants are administered for decreasing risk of stroke and systemic embolism. In this case the occurrence of intracranial bleeding is hard task for doctor. From the one side it is necessary to reverse the action of the drug for preventing the growth of hematoma. At the same time the discontinuation of therapy increases the risk of systemic embolism for patients with AF significantly. Clinical guidelines and studies have been reviewed about ICH during anticoagulant therapy. Nowadays there is no quality evidence about reversal of anticoagulant effects after ICH and optimal time of resumption of anticoagulant therapy. Firstly, we do not have large randomized controlled trials on this issue. The majority of clinical guidelines were based on retrospective studies and opinions of experts. Soon several randomized controlled trials will be finished and new data will be presented.
No takes yet. Share an insight, caveat, or question.
Герасименко et al. (2021) conducted a review in Atrial fibrillation after intracranial hemorrhage. Anticoagulation therapy was evaluated. Anticoagulation therapy reversal and optimal resumption timing after intracranial hemorrhage currently lack high-quality evidence from large randomized controlled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: